Publications by authors named "Jackson P Schuetz"
Purpose Of Review: This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.
Recent Findings: Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT.
Background: Conventional basophil activation tests (BATs) measure basophil activation by the increased expression of CD63. Previously, fluorophore-labeled avidin, a positively-charged molecule, was found to bind to activated basophils, which tend to expose negatively charged granule constituents during degranulation. This study further compares avidin versus CD63 as basophil activation biomarkers in classifying peanut allergy.
View Article and Find Full Text PDFArticle Synopsis
- Food allergies can cause serious reactions like anaphylaxis, and both innate and adaptive immune systems are involved in this process.
- Research found that natural killer (NK) cells show heightened activity in individuals with peanut allergies compared to those without.
- NK cells may play a crucial role in regulating allergic reactions, as their response relies on T cells, and oral immune therapy appears to reduce their reaction to peanut allergens.